Ike: Why Nigeria Must Intensify Fight Against Drug-Resistant Gonorrhoea

Dr. Ifeanyichukwu Samuel Ike, a Nigerian physician-epidemiologist based in Illinois, discusses the escalating threat of drug-resistant gonorrhoea in Nigeria. As a resident physician treating HIV/AIDS and sexually transmitted infections at a major hospital in Nigeria, he witnessed firsthand the interconnected nature of infectious diseases and their impact on patient care.

This experience ultimately led him to a career in public health, where he recognized the importance of data-driven interventions and community engagement in addressing large-scale health crises.

Ike's academic training in public health with a focus on infectious disease epidemiology exposed him to sophisticated surveillance platforms and analytical tools. He discovered a critical gap between the analytical capabilities in high-income countries and the scarcity of people who can interpret this data with clinical depth in resource-poor settings like Nigeria. He emphasizes that Nigeria's underfunded surveillance infrastructure makes it particularly vulnerable to the threat of antimicrobial resistance.

Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae, is now designated as an urgent threat by the CDC, placing it in the same category as antibiotic-resistant bacteria like carbapenem-resistant Enterobacteriaceae. Ceftriaxone, the last reliable first-line treatment for gonorrhoea, is already showing signs of resistance globally. If ceftriaxone becomes ineffective, Nigeria would face a crisis in treating sexually transmitted infections, as there are few effective alternatives.

The implications of this threat for Nigeria are particularly severe. The country already has one of the highest burdens of sexually transmitted infections in sub-Saharan Africa, and gonorrhoea is endemic. The widespread misuse and self-medication of antibiotics exacerbate the problem, accelerating the development of drug resistance.

Dr. Ike's research on antibiotic stewardship awareness among university students in Illinois revealed alarming low levels of knowledge, highlighting the need for education campaigns in Nigeria where antibiotics are often sold over the counter without prescription.

To address this growing crisis, Dr. Ike advocates for policy recommendations aligned with the CDC's CARB Action Plan. These include community education campaigns, institutional stewardship protocols, data-driven monitoring of antibiotic prescribing patterns, and regulatory measures to prevent the overuse of antibiotics. He emphasizes that these interventions are not affected by geographical location, making them equally applicable in Nigeria as they are in the United States.

Dr. Ike's message is clear: the threat of drug-resistant gonorrhoea is not a distant threat but a looming crisis that Nigeria must confront urgently. The consequences of inaction could be catastrophic, particularly for communities with limited access to healthcare. By implementing evidence-based strategies and strengthening disease surveillance, Nigeria can mitigate the impact of this emerging threat and safeguard the health of its population.